PharmaCyte Biotech, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joshua N. Silverman
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3960 Howard Hughes Parkway Las Vegas NV United States of America 89169
- IPO Date
- Jan 2, 2013
- CIK
- 0001157075
- Website
- pharmacyte.com
- Similar Companies
- Business
- PharmaCyte Biotech, Inc. (Nasdaq: PMCB) is a clinical-stage biotechnology company focused on developing and preparing to commercialize cellular therapies for cancer and diabetes using its proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. The company's core products and services encompass targeted therapies for pancreatic cancer and other solid tumors, wherein genetically engineered human cells encapsulated in Cell-in-a-Box® convert inactive prodrugs, such as ifosfamide, into active cancer-killing agents directly at the tumor site; a bio-artificial pancreas for Type 1 and insulin-dependent Type 2 diabetes, utilizing encapsulated genetically modified liver cells, stem cells, or beta islet cells that produce insulin in response to blood glucose levels; and emerging cannabinoid-based therapies for difficult-to-treat cancers like brain cancer, combining Cell-in-a-Box® with prodrug cannabinoids to optimize anticancer effects while minimizing side effects. Founded in 1996 and headquartered in Las Vegas, Nevada, PharmaCyte operates primarily in the United States, targeting patients with inoperable pancreatic cancer, other solid tumors, and diabetes through its platform technologies. In recent developments, PharmaCyte made a $7 million strategic investment in MyMD Pharmaceuticals, Inc. in September 2025 to support clinical advancement of its lead sarcopenia candidate; increased its stake in TNF Pharmaceuticals around a licensing deal for a light-speed computing platform in cryptocurrency applications in September 2025; successfully monetized its stake in Femasys Inc. in November 2025, bolstering its cash position; and issued amendments to its 2023 and 2024 financial statements in November 2025 to detail G Series Preferred Stock issuances, related warrants, employee benefit plan contributions, and design certificate changes.
Nuvilex (NASDAQ:PMCB) Trading 5.3% Higher – Here’s Why
Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL)
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
MyMD Pharmaceuticals Secures Strategic Investments
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Announces Final Results of Tender Offer
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation